Liminatus Pharma Inc.: Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
Liminatus Pharma (Nasdaq: LIMN) said its shares transferred from the Nasdaq Global Market to the Nasdaq Capital Market effective Aug. 4, 2026, keeping the ticker LIMN. Nasdaq’s Hearings Panel granted an extension to regain compliance with the minimum bid price rule, with a deadline of Sept. 3, 2026.
How this was made
The 30-second read
Why it matters
The key tradable element is the updated compliance timeline. The transfer keeps the stock trading on Nasdaq under the same ticker (LIMN), but the company must demonstrate compliance by Sept. 3, 2026 to avoid further listing consequences.
Market read
This is a concrete exchange-listing risk update with a specific new deadline, which can change the stock’s delisting-risk premium and near-term trading behavior.
What to watch
Bid-price compliance can be influenced by financing, reverse splits, or sustained trading-volume improvements, none of which are detailed here.
Background
Liminatus Pharma was moved from Nasdaq Global Market to Nasdaq Capital Market due to minimum bid price noncompliance, and the Nasdaq Hearings Panel granted additional time to fix it.
Ticker impact
Liminatus transferred from Nasdaq Global Market to Nasdaq Capital Market and received an extension until Sept. 3, 2026 to regain bid-price compliance.
Likely supports downside risk in the near term versus an immediate delisting scenario, but may cap upside until the company demonstrates bid-price compliance by Sept. 3, 2026.
The article is a primary listing-compliance update with a specific new compliance deadline, which typically affects risk premium and liquidity expectations more than fundamentals.
Market effects
For small-cap biopharma, Nasdaq compliance actions can signal ongoing liquidity/financing risk, influencing sector risk appetite for similar issuers.
Primarily US microcap listing and liquidity dynamics; limited direct regional spillover.
Low global relevance; mainly affects US trading venues and delisting-risk pricing.
Counterpoint
The extension may be viewed as a temporary reprieve, not a resolution, so traders may still fade rallies until bid-price compliance is actually achieved.
Key entities
- companyLiminatus Pharma, Inc.
Nasdaq-listed biopharmaceutical company developing cancer therapies; subject of the listing-compliance update.
- regulatorNasdaq Hearings Panel
Granted the company an extension to demonstrate minimum bid price compliance.
